Serial Changes of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Levels in Patients With Acute Respiratory Distress Syndrome

May 8, 2008 updated by: National Taiwan University Hospital

Serial Changes of sTREM-1 Levels in Patients With Acute Respiratory Distress Syndrome

The purpose of this study is to determine the impact of the serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) on etiology and prognosis of acute respiratory distress syndrome (ARDS)

Study Overview

Status

Completed

Conditions

Acute Respiratory Distress Syndrome

Detailed Description

The triggering receptor expressed on myeloid cells-1 (TREM-1), a member of the immunoglobulin superfamily, is upregulated on phagocytic cells in the presence of bacteria or fungi infection and weakly expressed in samples from patients with noninfectious inflammatory disorders. In addition, TREM-1 is shed from the membrane of activated phagocytes and can be found in a soluble form (sTREM-1) in body fluids. The level and serial change of a serum sTREM-1 from cirtical ill patients has been shown to be a good diagnostic and prognostic indicator of ventilation associated pneumonia (VAP) and severe sepsis.

Study Type

Observational

Enrollment (Actual)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Taiwan
- - Taipei, Taiwan, 100
    - National Taiwan University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients admitted into ICU of a medical center in Taiwan

Description

Inclusion Criteria:

Fulfill clinical diagnosis of ARDS
Require mechanical ventilation support

Exclusion Criteria:

Pregnant
Immunocompromised

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
all cause mortality Time Frame: 28 days	28 days
Septic or non-septic etiology Time Frame: At enrollment	At enrollment

Secondary Outcome Measures

Outcome Measure	Time Frame
CRP, lactate, WBC count, APACHE II score, LIS, SOFA score Time Frame: At enrollment	At enrollment
IL-1 beta, IL-8, TNF-alpha Time Frame: serial follow up at Day 1, 3, 5, 7, 14	serial follow up at Day 1, 3, 5, 7, 14

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Taiwan University Hospital

Investigators

Principal Investigator: Chao-Chi Ho, Department of Internal Medicine and Emergency Medicine, National Taiwan University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2007

Study Completion (ACTUAL)

March 1, 2008

Study Registration Dates

First Submitted

November 12, 2007

First Submitted That Met QC Criteria